Get the Stockscreener App
5.93
3.73%
-0.23
After Hours:
5.95
0.02
+0.34%
Enanta Pharmaceuticals Inc stock is traded at $5.93, with a volume of 176.86K.
It is down -3.73% in the last 24 hours and up +2.42% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$6.16
Open:
$6.12
24h Volume:
176.86K
Relative Volume:
0.87
Market Cap:
$126.78M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-1.198
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
+2.07%
1M Performance:
+2.42%
6M Performance:
-31.05%
1Y Performance:
-50.58%
1-Day Range:
$5.885
$6.18
1-Week Range:
$5.70
$6.225
52-Week Range:
$4.09
$17.23
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.93 | 124.20M | 66.59M | -104.93M | -96.48M | -4.95 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech
Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace
Enanta to present RSV drug study results at ESPID 2025 - Investing.com
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta stock price target raised to $23 by JMP - Investing.com Canada
Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks
Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times
(ENTA) Trading Report - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN
11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey
JMP Securities maintains Enanta stock with $21 target - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
(ENTA) Investment Report - news.stocktradersdaily.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan
How To Trade (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Business Wire
Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire
Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):